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Abstract 
 
Acute Myeloid Leukemia (AML) is a cancer of overproliferative blood cells and is the most 
common type of blood cancer to occur in adults.  AML patients are commonly treated with 
chemotherapeutic approaches. Although chemotherapy drugs are effective at limiting growth of 
leukemia cells, the pathways that they target are common in all proliferating cells and as a result, 
healthy proliferative tissue is also damaged.  Currently, the identification and development of 
therapies that specifically or preferentially impact growth of leukemia cells is in high demand. 
Alisertib (MLN8237), an inhibitor of the mitotic kinase Aurora A is one potential drug that is 
currently being investigated clinically as a co-therapeutic for AML.  AML cells have been 
reported to exhibit high levels of Aurora A, and so are hypothesized to be exquisitely sensitive to 
inhibition of this mitotic regulator.  However, the cell biological impact of Aurora A inhibition in 
AML cells has not been investigated, and it is unclear if Aurora A expression levels alone may 
be a good predictor of sensitivity to Alisertib. 
 
Our studies have focused on exploring the molecular effects of Aurora A inhibition, and 
investigating cellular biomarkers, in addition to Aurora A levels, that may predict drug sensitivity 
in AML patients.  Our initial correlative studies in a panel of AML cell lines, does not show a 
clear correlation between Aurora A levels and Alisertib sensitivity.  Instead, our results suggest 
that an increased centriole number confers resistance of AML cells to Alisertib. We will continue 
to define centriole number as a potential biomarker through ongoing approaches that will test 
both the contribution of Aurora A levels and centriole number, both in isolation and in 
combination, on Alisertib sensitivity.  
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1. Introduction  
 
Acute Myeloid Leukemia (AML) is a type of blood cancer that occurs when the bone marrow 
makes abnormal myoblasts, platelets or red blood cells. These abnormal cells continue to 
develop and accumulate within the blood vessels, which can result in anemia or easy bleeding. 
According to the American Cancer Society, AML is the most common type of blood cancer to 
occur in adults, and is generally seen in adults above the age of 67. The percent of individuals 
that will survive five years after AML diagnosis is approximately 27%. Most of the individuals will 
initially experience flu-like symptoms, including fever, sweats or body aches.  According to the 
Seattle Cancer Care Alliance, in order to diagnose AML, several tests are needed, including a 
bone marrow biopsy, complete blood cell counts or tests for genetic abnormalities. Currently, 
chemotherapy is the most common treatment given to AML patients. This treatment is generally 
given in two steps, and the purpose of the treatment is to use chemotherapy drugs to eradicate 
all of the leukemic cells. However, chemotherapeutic approaches do not specifically target 
cancer cells but instead target all proliferating cells and cause side effects that impact the health 
of the patient as stated by the American Cancer Society. Targeted therapies are now being 
pursued, that may exclusively, or preferentially, target cancer cells through the use of an Aurora 
A kinase inhibitor called Alisertib.  
 
Aurora A kinase is part of a family of serine/threonine kinases that are vital in cell cycle 
regulation and mitosis (Fu et al., 2007).  Aurora A kinase’s function is to control mitotic entry, 
and recruit components for centrosome maturation. Aurora A plays a critical role in the 
formation of a bipolar mitotic spindle, which is crucial for the proper separation of the sister 
chromatids to each of the daughter cells (Dutertre et al., 2002). When Aurora A kinase is 
overexpressed, centrosome amplification, cytokinesis inhibition and aneuploidy can result.  
Aurora A kinase has been found to be overexpressed in a variety of cancers, including breast, 
colon, and AML. Its role within the cell, and together with its overexpression profile in a range of 
cancers suggest that Aurora A is a promising drug target.  
 
Previous studies have shown that the inhibition of Aurora A kinase function through depletion or 
inhibition results in mitotic spindle assembly defects (Manfredi, et al., 2011). Loss of Aurora A 
function disrupts mitotic spindle formation and results in spindles with one or multiple spindle 
poles. The Aurora A kinase inhibitor that this paper focuses on is Alisertib (or MLN8237). 
Alisertib has been shown to disrupt the growth of Acute Myeloid Leukemia (AML) cells, and a 
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common phenotype of Alisertib-treated AML cells is a monopolar spindle pole (Moore, A.S, et al, 
2010).    However, not all AML cells exhibit the same degree of Aurora A amplification, or 
spindle morphology defects and it remains unclear in which contexts Aurora A inhibition may 
have the greatest therapeutic value. In this Major Qualifying Project we aim to define the cellular 
implications of Aurora A kinase inhibition with Alisertib, and to investigate cellular biomarkers 
that predict drug response. In addition biomarkers that could suggest Alisertib would be more or 
less effective are considered. Lastly, this project explores the possibility that centriole number, 
independent of Aurora A level indicates the responsiveness of an AML cell to Alisertib.   
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2. Background 
2.1 Acute Myeloid Leukemia (AML) 
The National Cancer Institute defines hematopoietic stem cells, also known as blood stem cells, 
as immature cells that have the ability to self-renew and to differentiate into any type of blood 
cell. These cells are generally identified in the bone marrow, the soft, sponge-like tissue in the 
center of bones. Hematopoietic stem cells first differentiate into blood cells of two different 
lineages, the lymphoid and myeloid, which give rise to many other types of cells. The lymphoid 
stem cells further differentiate into T cells, B cells, and natural killer (NK) cells. The myeloid 
lineage gives rise to megakaryocytes, erythrocytes (MegE), as well as granulocytes (Iwaski and 
Akashi, 2007). Mature blood cells have short life-spans, and new blood cells are derived from 
hematopoietic blood cells (Robb, 2007). 
 
According to the Johns Hopkins 
Comprehensive Cancer Center, blood 
cancers usually develop in the bone 
marrow, and it affects both the 
production and function of blood cells. 
Each type of blood cancer is due to 
defects in specific cell lineages. The 
hematopoietic stem cells replace the 
normal blood cells as they age and die. 
However, when an individual has blood 
cancer, this process is corrupted. 
Hematopoietic stem cells may not 
grow or differentiate normally, or the 
immune system will attack normal 
tissue. According to the American 
Society of Hematology, in all three 
different types of blood cancers - lymphoma, myeloma, and leukemia - the development of 
blood cells is hindered by the uncontrolled growth of a progenitor.  
 
 
The Mayo Clinic defines acute myeloid leukemia (AML), or acute myelogenous leukemia, as a 
type of blood cancer that occurs in bone marrow. According to the National Cancer Institute, 
Figure 1. Differentiation of Hematopoietic Stem Cells  
Blood stem cells can differentiate into two lineages of blood 
cells: Myeloid and Lymphoid. Each lineage is responsible for 
the production of different blood cell types 
 
Retrieved from: Winslow, Terese. National Cancer Institute. 2007 
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AML progresses rapidly and only affects the myeloid lineage of cells, therefore affecting the 
development of red blood cells, platelets and myeloblasts.  These abnormal cells accumulate in 
the blood vessels and take the space of healthy blood cells. This might lead to anemia and easy 
bleeding.  
2.1.1 Prevalence, Risk Factors and Symptoms 
According to the World Health Organization, the incidence of AML worldwide in 2012 was 
351,965 people.  AML commonly occurs at older ages, with an average of 67 years old, and the 
lifetime risk for its occurrence is between 0.5 and 1%. According to the National Cancer Institute, 
the average 5-year survival rate for people with AML is 27%. 
 
During the early stages of AML, patients will experience symptoms similar to the flu including 
fevers, sweats and body aches. The symptoms can vary based on the deficiency of various 
blood cell types. For example, patients will low white blood cells will suffer from bacterial or viral 
infections, and have occurrences of mouth inflammation or sores. To determine if the patient 
has AML, several tests have to be completed to accurately diagnose the patient. According to 
the Seattle Cancer Care Alliance, these can include bone marrow biopsies, complete blood 
counts, and a polymerase chain reaction to test for the presence of a certain chromosomal 
translocation. Other tests can be used to detect genetic abnormalities, like examining the FLT3 
gene for example. The FLT3 gene, when abnormal, has been correlated with poor prognosis in 
AML patients. In addition to the FLT3 gene, Aurora A kinase has been observed to be 
overexpressed in AML compared with normal hematopoietic stem cells (Kim et al., 2012).  
 
To date, a high risk factor associated with the development of AML is smoking. Substances 
present in tobacco do not only affect the cells that are in direct contact with them, such as the 
lung cells, but it also can affect the cells in the bloodstream, since the smoke diffuses from the 
lungs to the blood vessels (Lichtman, 2007). There are other risk factors that could increase the 
probability of AML development, including prolonged exposure to specific chemotherapy drugs 
such as alkylating agents, platinum agents, and topoisomerases II inhibitors. These can be used 
as treatments for other cancers. In addition, having blood diseases (i.e polycythemia vera, and 
idiopathic myelofibrosis) and genetic syndromes (i.e. down syndrome and fanconi anemia) have 
been linked to an increased risk of developing AML, especially when chemotherapy drugs have 
been used, as reported in the American Cancer Society. Although a few of the patients present 
some of these risks factors, their presence alone is not sufficient to cause cancer. AML 
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commonly develops after an accumulation of mutations in DNA over time, which can happen 
because of unknown reasons. While translocations are the most common chromosomal 
changes found in AML, many others can also occur, such as deletions, inversion, insertions or 
duplications.  
2.1.2 Current Treatments 
Currently, the most common type of treatment for AML is chemotherapy, which can be followed 
by a stem cell transplant. The chemotherapy is conducted in two steps: induction and 
consolidation. Induction is the first phase, and aims to eliminate leukemic cells from the blood, 
get rid of all signs of disease for an extended time (also known as remission) and to increase 
the healthy blood count to within a normal range. Generally, doctors will use two or more 
chemotherapy drugs to treat AML, as each individual drug utilizes different methods to destroy 
the cancer cells. Therefore, combining drugs can strengthen the treatment’s effectiveness.  The 
second step, consolidation, is conducted after the patient has recovered from induction. The 
second phase is targeted at killing the small population of leukemia cells that may remain after 
induction. According to the Leukemia & Lymphoma Society, without consolidation, or 
“postremission therapy”, AML has a higher probability of returning.  
 
Common chemotherapy drugs include cytarabine or anthracycline drugs. Cytarabine, once 
phosphorylated and is incorporated into DNA, will block DNA elongation by inhibiting DNA 
polymerase, and results in a decrease of DNA replication and repair (Fitzakerley, 2015). 
Anthracycline drugs primarily act through intercalation. Intercalation inserts an aromatic ring 
between DNA base pairs, compromises replication, and results in cytotoxicity (Barton et al, 
1991).  However, both of these chemotherapies can also harm other types of proliferative cells. 
According to the American Cancer Society, chemotherapy drugs can result in side effects 
including nausea, hair loss, mouth sores, fatigue, increased bruising and risk of infections. 
 
Although the patient survival has increased over the years, the current treatments are not 
effective enough in patients older than 60 in which AML is more prevalent. Because of this, 
there is a need for the discovery of new targets for the development of new effective 
therapeutics.  
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2.2 Acute Myeloid Leukemia and Aurora A Kinase 
In normal human cells, the cell cycle consists of four phases: S phase (chromosomal 
duplication), M phase (chromosomal separation) and two Gap phases (G1 and G2) that 
separate both S and M phases (see Figure 2)(van den Heuvel, 2005). The M phase consists of 
four stages: prophase, metaphase, anaphase, and telophase (O'Connor, 2008). During 
prophase, the chromosomes begin to condense, the nuclear envelope starts to break down, and 
the mitotic spindle begins to form. Following prophase, the cell proceeds to pro-metaphase 
where chromosomes attach to the spindle microtubules and begin to congress towards the 
center of the cell. Once all chromosomes have fully attached to a bipolar spindle and aligned at 
the spindle center, the cell is said to be in 
metaphase. The microtubules nucleated at the 
centrosomes attach to protein structures known 
as kinetochores. Attached chromosomes orient 
so that each replicated chromosome is 
associated with microtubules nucleated from a 
single centrosome/spindle pole. This attachment 
and alignment satisfies the spindle assembly 
checkpoint and enables the cell to enter 
anaphase. During this phase, cohesion between 
replicated chromosomes is lost and the sister 
chromatids are pulled apart and towards 
different cell poles. Following anaphase, 
nuclear envelopes reform around decondensing 
chromatin and cyotokinesis cleaves the dividing 
cell into two genetically identical daughters 
(O'Connor, 2008). 
 
Centrosomes are organelles that organize 
microtubules and are involved in the process of 
cytokinesis (O’Connor & Adams, 2010). The 
centrosomes are composed of three parts: two centrioles (a mother and a daughter centriole), a 
matrix that connects the two centrioles, and pericentriolar material. Centrosomes are duplicated 
during S phase (Figure 2).  The cell, before entering mitosis, contains four centrioles that are 
organized in two centrosomes.  As the cell moves into mitosis, the centrosomes move apart 
Figure 2. Aurora A Kinase and Centrosome 
Separation 
Centrosomes are duplicated during S phase, move apart upon 
mitotic entry where they become microtubule nucleating 
centers that make up functional spindle poles 
 
Retrieved from: Dutertre, Stephanie, Simon Descamps, and 
Claude Prigent. "On the Role of Aurora-A in Centrosome 
Function."Nature.com. Macmillan Publishers, 9 Sept. 2002. 
Web. 01 Feb. 2017. 
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towards opposite sides of the cell, where they nucleate and organize the microtubules of the 
mitotic spindle. After cytokinesis, each of the daughter cells contains a single centrosome with 
two centrioles. Centriole duplication 
is mainly regulated by Plk-4, a 
member of the polo like kinase family, 
which is localized in the centrioles 
(Holland, et. al., 2010). The active 
levels of this kinase controls the 
number of centrioles that will be 
formed during mitosis: while 
decreasing levels of active Plk-4 
would cause the cells to 
progressively lose centrioles, an 
overexpression of its active levels 
would cause the creation of multiple 
centrioles in one cell cycle (Figure 3) 
(Holland, et. al., 2010).  
 
2.2.1 Aurora Kinases Function and Regulation 
Aurora kinases are a family of serine/threonine kinases that have been implicated in cell cycle 
control, and are vital during mitosis (Fu et al., 2007). These kinases are enzymes that control 
the functions of many substrates by phosphorylation. There are three members of the Aurora 
kinase family: Aurora A, Aurora B, and Aurora C (Fu et al., 2007). The activity of Aurora kinases 
is closely regulated; as disruption or deregulation of these kinases can lead to genetic instability 
due to defects in centrosome function, spindle assembly and chromosomal alignment. Aurora A 
plays a role in mitotic spindle assembly through facilitating centrosome maturation by recruiting 
various components such as y-tubulin (Fu et al., 2007). Aurora B regulates spindle assembly, 
chromosome separation, and is also known to play a role in cytokinesis. For example, when 
Aurora B kinase is depleted the cell will become polyploid (Fu et al., 2007). According to the 
National Center for Biotechnology Information, Aurora C has been known to play a role in 
microtubule organization in centrosome and spindle function during mitosis by forming 
complexes with Aurora B and centromere proteins. In many human cancers, the expression and 
activity of the Aurora kinases is increased, suggesting that they may play a role in tumorigenesis, 
and has become the focus of many anti-cancer drugs and treatments (Fu et al., 2007).  The cell 
Figure 3. Effect of overexpression of centrosome proteins 
Overexpression of Plk-4 causes centriole amplification at the base of the 
mother centriole, also known as the rosette type amplification, in which the 
daughter centrioles form around the proximal end of the mother centriole. 
 
Retrieved from: Tang, Tang K. "Centriole biogenesis in multiciliated cells." Nature cell 
biology 15.12 (2013): 1400-1402. 
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cycle is primarily regulated by cyclin-
dependent kinases, also known as CDKs. 
CDKs are further regulated by 
phosphorylation, degradation of proteins 
that inhibit cyclin, and degradation of 
cyclins, among others (van den Heuval, 
2005). The mitotic events of the cell cycle 
have other regulatory molecules besides 
CDKs, such as polo-like kinases, and 
aurora kinases. Aurora A kinase, for 
example, functions to control mitotic entry, 
which happens after the activation of 
CDK1 (Figure 4). This control is done 
indirectly, by interactions with Polo-like 
kinase 1 (Plk-1), a cell cycle kinase that 
regulates processes such as centrosome 
maturation, spindle assembly and 
chromatin cohesion (Bruinsma et al., 
2014). Plk-1 is located at the centrosomes 
and mitotic spindle. Plk-1 is switched on by phosphorylation at residue T210 during G2 phase, 
reaching its maximum activity during mitosis, after it is phosphorylated at residue T210 
(Bruinsma et al., 2014). The phosphorylation of this residue is done by the Aurora A-Bora 
complex. The phosphorylation of residue T210 causes a change in the conformation of Plk-1 
that provides Aurora A enhanced access to residue T210 (Fu, Jiang & Zhang, 2010). Inhibition 
of Aurora A has been shown to prevent the activation of Plk-1 and lead to the formation of 
monopolar spindles.  
 
During S phase, Aurora A localizes on duplicated centrosomes, and remains there until the 
beginning of G1 during the following cell cycle.  While located on the centrosomes, Aurora A 
has three functions.  First, as shown by experiments performed in Xenopus and in Drosophila, 
Aurora A contributes to centrosome separation.  In these two animals, inactivation of Aurora A 
results in the formation of monopolar spindles, with the centrosomes failing to separate (Duterte 
et al., 2002). The mechanism by which Aurora A contributes to centrosome separation is 
through phosphorylation of Eg5, a protein required for centrosome separation to occur. A 
Figure 4. Role of CDK, Aurora A Kinase and Polo-
Kinase 1 
CDK1 activates the Aurora Bora complex, which 
leads to the phosphorylation and activation of PLK1. 
This results in the phosphorylation of residue T210  
 
Retrieved  from:  Fu, J., Jiang, Q. & Zhang, C. (2010) Collaboration 
of Mitotic Kinases in Cell Cycle Control. Nature Education 3(9):82 
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second function of Aurora A at the centrosomes is to ensure that centrosomes mature after they 
separate and before mitosis. This maturation includes the recruitment of proteins, such as y-
tubulin and centrosomin, to the centrosome to take part in its structure as well as to preserve its 
functionality during and after mitosis (Duterte et al., 2002). Lastly, Aurora A recruits and 
phosphorylates TACC3 at the centrosome. TACC3 is a protein that promotes microtubule 
stabilization (Lioutas & Vernos, 2013). This interaction contributes to the organization and 
stabilization of microtubules (Fu et al., 2007). 
 
Both the localization and activity of Aurora A is carefully regulated to ensure that it correctly 
functions within the cells. In 
normal cells, Aurora A is down-
regulated through APC/C-Cdh1 
dependent, proteasome-
mediated proteolysis. The 
degradation of Aurora A by 
APC/C-Cdh1 requires a 
destruction box in the C-
terminal region and a motif in 
the N-terminus (D'Assoro et al., 
2016). Aurora A is a major 
contributor to the proper 
segregation of the daughter 
cells during mitosis and 
Deregulation of its localization 
and activity can lead to 
abnormal spindle morphology 
and promote tumorigenesis 
(Duterte et al., 2002).  
2.2.2. Aurora A Kinase Overexpression and Effects in the Cell Cycle 
The Aurora A kinase gene is located in the 20q13 chromosome region, and is amplified and 
overexpressed in many cancers including breast, colon and ovarian cancers, leading to the 
overexpression of Aurora A kinase (Duterte et al., 2002). In a large majority of these cancers, 
Centrosomes duplicate during S phase, and move apart during 
G2/M phase. Aurora A contributes to centrosome separation  
during G2 phase.  
 
Retrieved from: Wang, Gang, Qing Jiang, and Chuanmao Zhang. "The Role of 
Mitotic Kinases in Coupling the Centrosome Cycle with the Assembly of the Mitotic 
Spindle." Journal of cell science, vol. 127, no. Pt 19, 2014, pp. 4111-
4122doi:10.1242/jcs.151753 
Figure 5. Diagram of Centrosome Duplication and Aurora A localization 
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the localization of Aurora A is diffused, being present in other parts of the cell such as the 
cytoplasm, and not being concentrated in the nucleus (Duterte et al., 2002).  
 
Centrioles are duplicated during S phase 
concurrent with DNA replication (Figure 5). The 
cell, therefore, contains four centrioles that are 
organized into two centrosomes throughout G2 
and mitosis. Aurora A kinase activity is not 
observed until the G2 phase, which implies that 
the kinase activity of Aurora A is not needed in 
order to duplicate the centrioles (Duterte et al., 
2002). While the activity of Aurora A is not 
required for centriole amplification, the 
overexpression of Aurora A has been shown to 
be sufficient for overamplification of centrioles 
(Meraldi et al., 2002). Recent studies show that 
cells overexpressing Aurora A and containing 
increased number of centrioles also have 
multiple nuclei, suggesting that these cells 
experience abnormal mitosis. Overexpression 
of Aurora A causes cells to form aberrant 
mitotic structures, and defective anaphases 
including the presence of anaphase bridges 
and cytoplasmic connections (Meraldi et al., 
2002). These aberrant anaphase defects cause 
the cells to fail cytokinesis, leading to the 
formation of tetraploid cells. Some cells that 
overexpress Aurora A kinase also overexpress 
Plk1 and Aurora B kinase, which have also 
been shown to cause an amplification of 
centrosomes (Meraldi et al., 2002). This 
amplification of centrosomes is also correlated with loss or mutation of p53, a tumor suppressor 
that plays a role during DNA damage response (Figure 6) (Goodsell, 2002). Cells that do not 
have a functional p53 protein have been shown to have a higher number of centrosomes when 
      
Errors in DNA replication, mitotic progression, or 
impaired mitotic checkpoints can result in an 
abortive mitotic exit. Cells lacking p53 can bypass 
G1 arrest cell death, and result in centrosome 
amplification 
 
Retrieved from: Meraldi, Patrick, Reiko Honda, and Erich 
A.Nigg. "Aurora-A Overexpression Reveals Tetraploidization as 
a Major Route to Centrosome Amplification in P53−/− Cells." 
The EMBO Journal. EMBO Press, 15 Feb. 2002. Web. 28 Feb. 
2017 
 
Figure 6. Diagram of Mitotic Errors 
 
 
P a g e  | 13 
 
Aurora A, Aurora B or Plk1 are overexpressed. This could explain why the overexpression of 
Aurora A leads to the formation of multiple centrosomes, as p53 loss would abrogate the 
checkpoint for aberrant mitotic cells, and permit their continued cycling (Meraldi et al., 2002).     
2.2.3 Aurora A Kinase Inhibition and Implications  
Currently, due to the role of Aurora A within the cell 
and its overexpression in many cancers, the effect 
of inhibition of Aurora A is being investigated.   It 
has been observed that Aurora A inhibition can 
lead to mitotic spindle assembly defects, such as 
monopolar spindle poles which activate the spindle 
assembly checkpoint and induce mitotic arrest 
(Bavetsias & Linardopoulos, 2015). Following a 
prolonged mitotic arrest, some cells undergo 
mitotic catastrophe. Other cells that ultimately exit 
mitosis and enter G1 will senesce or apoptose. 
However, not all cancer cells respond similarly to 
Aurora A inhibition and it remains unclear what 
features of a cancer cell may promote the preferred 
mitotic catastrophe or apoptosis, over a G1 arrest. 
There are multiple Aurora A inhibitors in clinical 
trials, including AT9283, PF-03814735, and 
Alisertib (or MLN8237).  
 
First, AT9283 is a heterocyclic molecule that 
inhibits aurora kinases, including both Aurora 
kinase A and B. This inhibitor is used as a therapy 
for many solid tumors and leukemic cancers, as it 
shows a reduction in the proliferative profile of 
leukemic cancers, as well as an induction of 
aneuploidy and apoptosis (Qi et al., 2012).  Second, PF-03814735 is a reversible inhibitor of 
both Aurora kinase A and B, and to a lesser extent FLT1, FAK, and TrkA which have been 
implicated in tumorigenesis in cancers such as leukemia and breast cancer. Small cell lung 
cancer and colon cancer are the most sensitive to PF-03814735, which works by blocking 
Figure 7. Alisertib Mechanism in vitro 
Alisertib inhibits Aurora A kinase, resulting in 
mitotic entry delay. This leads to spindle 
bipolarity defects, which can lead to 
apoptosis or cell cycle reentry 
 
Retrieved from: Niu, Huifeng, Mark Manfredi, and Jeffrey 
A. Ecsedy. "Scientific Rationale Supporting the Clinical 
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Kinase Inhibitor Alisertib in Cancer." Frontiers in 
oncology, vol. 5, 2015, pp. 189, 
doi:10.3389/fonc.2015.00189  
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cytokinesis and, therefore, preventing cell proliferation and creating cells that are multinucleated 
(Jani et al., 2010).  Lastly, MLN8237, also known as Alisertib, is the first oral and selective 
inhibitor of Aurora A kinase. It shows more than a 200-fold increased specificity for Aurora A 
kinase than Aurora B kinase (Niu et. al., 2015). Alisertib mechanism of action has been studied 
in both in vitro and in vivo models (Figure 7). The main consequences of Alisertib treatment are 
either mitotic arrest or apoptosis, which are events that happen after the cells undergo changes 
in the phenotype related with an inhibition of Aurora A kinase (Niu et. al., 2015). First, cells 
trying to undergo mitosis under Alisertib treatment experience a delay in its entry, followed by an 
increase in the number of cells that contain tetraploid DNA content. When the cells enter mitosis 
they tend to exhibit chromosomal defects such as chromosome misalignment, and form 
monopolar and multipolar spindle poles. The fate of the cells that undergo a first round of 
mitosis is either apoptosis, cytokinesis that causes aneuploidy to the daughter cells, or mitotic 
slippage, which consists in the exit of mitosis without undergoing cytokinesis. In the two possible 
outcomes that do not represent cell death, the daughter or resulting cell usually expresses 
micronucleation or 
multinucleation phenotypes (Niu 
et. al., 2015). Only a portion of 
these cells will re-enter the cell 
cycle (experiencing the same 
chromosomal misalignments and 
possible apoptosis) while some 
others will undergo cell death or 
stay in a state of senescence, in 
which cells are metabolically 
active but do not undergo any 
type of cell growth (Campisi, 
2013). 
 
Previous work has shown that 
Alisertib, at clinically achievable 
concentrations, impairs the 
growth and survival of AML cell 
Figure 8. AML Cell Viability at Concentrations of Alisertib 
All AML cell lines had significantly larger decreases of cell viability 
as the concentration of Alisertib increased compared with the 
control cell line PBMC.  
 
Retrieved from: Kelly, Kevin R. et al. “Targeting Aurora A Kinase Activity with the 
Investigational Agent Alisertib Increases the Efficacy of Cytarabine through a 
FOXO-Dependent Mechanism.” International journal of cancer. Journal 
international du cancer 131.11 (2012): 2693–2703. PMC. Web. 18 Jan. 2017. 
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significantly more than normal Peripheral Blood Mononuclear Cells (PBMC) cells (Figure 8). 
Alisertib was also shown to increase the percentage of AML cells that experienced an induction 
of apoptosis (Kelly et al., 2012).  
 
Recently, a phase I trial conducted at Massachusetts General Hospital evaluated the safety and 
tolerability of Alisertib when combined with chemotherapy for patients diagnosed with AML. The 
treatment during this clinical trial involved infusions of cytarabine for 7 days, and another 
chemotherapy drug, idarubicin, for 3 days. After the cytarabine infusions on day 7, patients were 
administered oral doses of Alisertib for 7 days. Overall, the researchers observed that Alisertib 
was well tolerated. The results showed that overall 86% of the patients that participated in the 
study achieved complete remission. Within the patient group, 7 out of 8 patients that were over 
the age of 65 achieved a complete remission. In addition all patients that were diagnosed with 
high-risk AML achieved complete remission (Fathi et al., 2016).   
 
Despite the success of the clinical trial, in vitro studies have demonstrated that the degree of 
sensitivity of AML cell lines varied, suggesting that the unique background of individual cell 
types may be a contributing factor in the cellular response to Alisertib (Kelly et al., 2012).  
Interestingly, previous research has failed to show a direct relationship between Aurora A 
expression levels and sensitivity to Alisertib. The reason for this remains unknown. The purpose 
of this project is to explore biomarkers that indicate drug efficacy and explore the cellular 
implications of inhibiting Aurora A kinase by Alisertib.    
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3. Materials and Methods 
3.1 Subculture of Human Tissue Culture 
 
Table 1. AML and Control Cell Line Derivation  
(Obtained from ATCC cell lines) 
 
Cell Line Tissue Disease Patient Details Treatments Category 
RPE-1 Retina, eye None Female None Non-
Transformed 
PC-9 Lung 
Adenocarcino
ma Unknown None Transformed 
SAOS-2 Bone Osteosarcoma 
Female, 11 
years old, 
Caucasian 
RTG, 
methotrexate, 
Adriamycin, 
vincristine, 
Cytoxan and 
aramycin-C 
Transformed 
K562 Bone Marrow 
Chronic 
Myelogenous 
Leukemia 
Female, 53 
years old 
None Transformed 
HL60 Peripheral 
Blood 
Acute 
Promyelocytic 
Leukemia 
Female, 36 
years old, 
Caucasian 
None Transformed 
KG1α Bone Marrow 
Acute 
Myelogenous 
Leukemia 
Male, 59 years 
old, Caucasian None Transformed 
U937 Pleura effusion 
Histiocytic 
Lymphoma 
Male, 37 years 
old, Caucasian None Transformed 
THP1 Peripheral 
Blood 
Acute 
Monocytic 
Leukemia 
Male, 1 year 
old 
None Transformed 
 
In the experiments and results discussed below, a variety of AML and control cell lines are 
utilized. The control cell lines include RPE-1, PC-9 and SAOS-2.  RPE-1 act as a negative 
control, as this cell line is non-cancerous and has not been reported to have any abnormal 
expression of Aurora A kinase. PC-9 and SAOS-2 both are cancerous tissues, and therefore, 
may have an overexpression of Aurora A. However, these will act as positive controls and help 
to determine cellular factors that may be specific to AML (Table 1).  
 
Each cell line was subcultured at a ratio 1:5 every 72 hours. For adherent cell lines (RPE-1, 
RPE-PLK4, PC9, and SAOS2), the media was aspirated out, and 2 mL of 1XPBS was used to 
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rinse the cells.  The 1XPBS was then aspirated out and 2 mL of trypsin was added to the cells.  
The cells were left at 37C for 5 minutes. After the incubation period, 8 mL of media was added 
to the trypsinized cells. Two mL of this cell suspension was removed, placed into a new T75 
flask, and the total volume increased to 10mL with media.  All suspension cell lines (U937, 
THP1, K562, and KG1α) were subcultured by moving 2 mL out of the current flask, transferring 
the 2mL to a new T75 flask, and bringing up the volume to 10mL with fresh media.  
3.2 Fixing and Staining AML Cells for Immunofluorescence   
Polylysine coverslip preparation 
Coverslips were immersed in 10% acetic acid for 10 minutes in a shaking tray. Afterwards, the 
acetic acid was removed and the coverslips were washed with water twice by shaking for 10 
minutes. Next, the coverslips were incubated in 10% polylysine (diluted in water) for 10 minutes.  
The 10% polylysine solution was removed and the coverslips were dipped briefly in water, and 
then air dried in a rack before use.  
 
Immunofluorescence  
In 2mL of media, 1.0 x 106 cells of each AML cell line and the RPE cells were plated. Each well 
received a polylysine coated coverslip. 24 hours after plating the cells, Alisertib was added so 
the final concentrations were 0nM (untreated), 25nM, 50nM, and 100nM. The cells were 
exposed to Alisertib for 18 hours. After exposure to Alisertib, the plates containing AML cells 
were centrifuged at 1000 rpm for 5 minutes to promote adherence of cells to the coverslip. Each 
coverslip was transferred to a dish containing 1mL ice cold methanol and was incubated at -
20ºC for 15 minutes. The plates were then centrifuged again at 1000 rpm for 5 minutes. After 
centrifugation, the methanol was removed, and coverslips were washed with 1mL of 1x PBS. 
Coverslips were then blocked in 1mL TBS/BSA for 20 minutes at room temperature.  
 
Primary antibodies were prepared by diluting dm1α (Santa Cruz Biotechnology, Reference 
Number: SC-32293) and centrin-2 (Santa Cruz Biotechnology, Reference Number: SC-27793R) 
1:1000 and 1:200, respectively, in 1mL of TBS/BSA. The coverslips were placed in a humid 
chamber and 100 µL of primary antibody was added to each coverslip for 90 minutes. The 
coverslips were washed with TBS/BSA for 5-10 minutes. Secondary antibody was prepared at a 
1:1000 dilution in DAPI/TBS. The coverslips were incubated with 100 µL of secondary antibody 
in a humid chamber in the dark for 45-60 minutes. The coverslips were then washed with 
TBS/BSA for 5-10 minutes, and then were mounted on a slide with Molecular Probe Prolong 
 
 
P a g e  | 18 
 
Gold Antifade Reagent (Reference Number: P36934). Afterwards, each slide was viewed on a 
Nikon Ti at the objective 60X. To view the staining, channels DAPI, FITC, and TxRed were used 
to image the DAPI, centrin-2 and dm1-alpha staining respectively. For this experiment, there 
were three biological replicates, each containing two technical replicates.  
3.3 Observing Alisertib Impact on Acute Myeloid Leukemia Cells 
Viability Assay  
The five AML cell lines (U937, HL60, THP1, KG1α, and K562) and three control cell lines (RPE, 
PC9, and SAOS2) were treated with a range of Alisertib concentrations. 100 µL of media 
containing 6,000 cells were used in each well of a 96-well plate, and 100 µL of media or media 
with Alisertib concentrations of 10nM, 25nM, 50nM, 100nM, and 250nM were added. The 
viability assay contained three technical replicates in each plate and three biological replicates 
were done for each cell line. Resistant cell lines to Alisertib, U937 and K562, as well as the 
three controls were used for additional viability assays at Alisertib concentrations of 500nM, 
750nM, 1µM, with the same volume and number of cells. 
 
After three days of exposure to Alisertib, 20 µL of Thermo Fisher Presto Blue was added to 
each well.  After 2h, the plate was read on a PerkinElmer 2030 Explorer at 600 A.  
 
For this experiment, there were three biological replicates, each containing two technical 
replicates.  
 
FACS Analysis 
2.0 x 106 cells were plated in 10 cm dishes and media was added up to 10 mL. After 24 hours, 
the cells were treated with 100 ng/mL Nocodazole and with Alisertib concentrations of 100nM 
and 250nM for 16h. For only Alisertib treatment, the cells were plated and after 18 hours, were 
treated with 100 nM or 250 nM of Alisertib for 16h. Then 10uL of Thermo Fisher BrdU was 
added to the media for 1 hour. Afterwards, the media was collected in 15mL tubes and 
centrifuged at 1000rpm for 5 minutes, and the supernatant was aspirated. The pellet was 
resuspended in 150uL of PBS, followed by the addition of 350uL of cold 100% methanol. The 
500uL solution was then collected in an Eppendorf tube and stored at -20C.  
 
For analysis, the samples were spun at 800 rpm for 5 minutes, and the supernatant was 
aspirated. The pellet was washed twice in PBS, spinning and aspirating the supernatant 
between the two washes. 50 uL of 100 ug/mL ribonuclease and 200 uL of 50 ug/mL PI were 
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added to each sample. The samples were run on the Accuri C6 Flow Cytometer, with a 
threshold of 50,000 events.   
 
QPCR Protocol  
RNA was extracted from AML cell lines using Trizol (Ambion, Life Technologies) and 
complementary DNA was synthesizes using the Superscript first-strand synthesis system 
(Applied Biosystems – Life Technologies, Austin, TX, USA). Aurora A expression was then 
analyzed using primers (Table 2). To establish target-gene expression levels, complementary 
DNA was quantified using the SYBR green kit (Applied Biosystems – Life Technologies, Austin, 
TX, USA), gene-specific primers, as well as GAPDH specific primers using relative 
quantification analysis. The copy number of the gene of interest was normalized to the copy 
number for GAPDH.   
 
Table 2. qPCR Primer Sequences 
 
G
A
PD H
 
Forward 5’ – CCCTCTGGTGGTGGCCCCTT – 3’ 
Reverse 5’ – GGCGCCCAGACACCCAATCC – 3’ 
 
A
U
R
K
A
 
Forward 5’ – TTTTGTAGGTCTCTTGGTATGTG – 3’  
Reverse 5’ – GCTGGAGAGCTTAAAATTGCAG – 3’  
 
For this experiment, there were three biological replicates, each containing two technical 
replicates.   
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 4. Results 
 
4.1 AML Cell Lines are responsive to Nocodazole treatment  
 
Failure of consistent response of AML cells to Alisertib induced mitotic arrest may indicate an 
innate resistance of the cell line to respond to and maintain a mitotic arrest. To examine the 
susceptibility of the AML cells to mitotic arrest, Fluorescence Activated Cell sorting (FACS) 
analysis was used to monitor DNA content as a readout of cell cycle progression following 
treatment with the microtubule poison Nocodazole.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment with Nocodazole provided a significant enrichment of both the control cells and AML 
cells in mitosis, demonstrating that AML cells are responsive to conditions that perturb mitotic 
progression, leading to an enrichment of cells with 4N/mitotic DNA content. All of the cell lines 
still show a small percentage of cells that are not arrested, rather in G1 or S phase. Moreover, in 
some of the AML cell lines such as K562 and U937, we can observe the presence of cells in the 
region after the G2/M peak, suggesting that there are aneuploid cells (Figure 9).  
 
Figure 9. Nocodazole 
treatment arrests AML cell 
lines in mitosis 
 
AML cells are affected by 
microtubule poison 
Nocodazole, and are able to 
arrest in mitosis, stage of the 
cell cycle in which Aurora A 
kinase is active.  
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4.2 AML cells overexpressing total levels of Aurora A also express centrosome amplification  
 
Research studies have correlated the overexpression of Aurora A kinase in human cancers 
such as breast, color, and cervical cancer, with poor prognosis (Fu et al, 2013). Some AML cell 
lines have also been shown to 
exhibit Aurora A 
overexpression, usually 
because of an increase 
expression of the Aurora A 
kinase gene (AURKA) (Kim et 
al, 2012).    
 
Immunofluorescence 
microscopy was used in order 
to determine the percentage of 
mitotic cells in each of the cell 
lines. Immunofluorescence 
analysis using alpha tubulin 
and DAPI (DNA) staining to identify mitotic nuclei indicated that both the control and AML cell 
lines expressed an even number of mitotic cells, around 2% (Figure 10) 
 
Quantitative PCR was used in order to determine the levels of Aurora A in a panel of AML cell 
lines as well as RPE cells, used as a control cell line for baseline Aurora A expression levels. 
KG1α and THP1 showed a non-significant slight increase of Aurora A kinase expression in 
comparison to RPE. However, two of the cell lines, U937 and K562, showed a three and eight-
fold increase in Aurora A kinase expression, respectively. Aurora A is highly expressed during 
mitosis and changes in cell cycle distribution can influence the apparent comparative levels of 
AurA in different cell lines. To control for this possibility, qPCR analysis was used to determine 
the levels of Aurora A kinase mRNA following a 20h treatment with Nocodazole to enrich for 
mitotic cells (Figure 11).  
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AML + Control Cell Line Mitotic Index 
Immunoflouresence analysis was utilized to score mitotic index for 
AML and control cell lines. All AML cell lines had a mitotic index 
comparable to RPE-1 
 
Figure 10. Percentage of Cells in Mitosis using IF 
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Consistent analysis of 
asynchronous cells, 
nocodazole-treated 
population indicate that 
K562 and U937 still are 
the two cell lines that 
express higher Aurora A 
kinase expression. RPE-
1, SAOS-2, and PC9 cell 
lines were used as 
controls cells.  
 
High levels of Aurora A 
have been demonstrated 
to corrupt spindle 
structure and promote 
overduplication of 
centrioles. Therefore, to 
characterize how high 
Aurora A levels may 
impact spindle 
assembly, 
immunofluorescence 
microscopy was used 
to monitor spindle 
structure and centriole 
number. RPE-1 cells 
were used as a 
negative control and 
mostly expressed a 
normal mitotic bipolar 
spindle as well as two 
centrioles. Although 25% 
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Figure 12. Spindle Polarity of mitotic AML cells 
Spindle polarity differed depending on the AML cell line. While some cell lines (K562 
and THP1) expressed a majority of bipolar spindles, others (Hl60 and KG1α) 
exhibited a high number of monopolar spindles.   
 
Quantitative PCR analysis of Aurora A kinase expression in AML and 
control cell lines. K562 and U937 scored had significantly higher fold 
expression over the control cell line, RPE-1. Nocodazole treatment caused 
cell lines to show an increase in Aurora A expression, with K562 and U937 
expressing Aurora A the most.     
 
Figure 11. qPCR of Aurora A Expression in AML Cells over RPE-1 
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of the cells expressed more than two centrioles, this could be attributed to cells in late S or G2 
phases that have already duplicated their centrosomes but haven’t entered mitosis yet. Most of 
AML cell lines expressed a single centrosome with two centrioles, except for K562 and U937. 
These two AML cell lines that overexpress Aurora A kinase showed centriole amplification, a 
relationship that has been previously 
characterized. Aurora A 
overexpression can result in 
centrosome amplification, and lead to 
multipolar spindles and abnormal 
segregation of the chromosomes 
(Bavestias & Linardopoulos, 2015). 
Moreover, and consistent with the 
amplification of centrioles, K562 
exhibited an increased percentage of 
multipolar spindles during mitosis. 
Additionally, some of the cell lines that 
express normal levels of Aurora A as 
well as centrosomes, such as HL60 
and KG1α, exhibited an increased amount of monopolar spindles during mitosis.  
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Figure 14. Number of centrioles in control and AML cells from 
Immunofluorescence analysis 
Immunofluorescence analysis was used to determine the number of 
centrioles that AML cell lines express. More than 70% of U937 and 
K562 cells exhibit amplification of centiroles.  
 
Figure 13. Immunofluorescence analysis of centrosome in RPE and AML cell lines                                         
Immunofluorescence analysis showed U937 and K562 overexpressed number of centrosomes during interphase  
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Given the well-documented role for Aurora A in centriole duplication, regulation of mitotic 
spindle formation, and mitotic progression, Aurora A has been proposed to be a promising 
target for novel AML therapeutic approaches (Fu et all, 2007). However, it remains unclear to 
what extent Aurora A over-expression, or additionally, associated cellular phenotypes, may 
indicate a likely response of the patient to therapeutic approaches that inhibit Aurora A function.  
 
4.3 AML cell lines that amplify centrosomes are more resistant to Alisertib treatment  
 
Because of Aurora A being suggested as a possible target for the treatment of cancers and 
tumors that overexpress it, the development of drugs that inhibit Aurora A have been used as 
part of many clinic trials. Alisertib is characterized for being one of the most specific inhibitors to 
date and it is being used in AML patients undergoing clinical trials. Because of its specificity, 
Alisertib was used in our experiments to determine what are the implications of inhibiting Aurora 
A expression in AML cell lines.  
 
In order to examine the specificity of Alisertib and its capacity to inhibit active Aurora A 
(phosphorylated Aurora A or pAurA), we performed western blots using the AML cell line that 
expresses the highest level of Aurora A kinase, K562, in four different conditions: untreated, 
nocodazole treated, 100nM 
Alisertib treated, and both 
nocodazole and 100nM 
Alisertib treated. Treatment 
with nocodazole, a 
microtubule poison, arrests 
cells in mitosis (Figure 15), 
the stage of the cell cycle in 
which Aurora A is 
phosphorylated and active. 
Treatment with nocodazole 
shows an increase in active 
Aurora A when compared 
with the asynchronous cells. 
Qualitatively, Alisertib treatment at a 100nM concentration reduces phospho Aurora A to 
Figure 15 Alisertib inhibits the phosphorylation of Aurora A               
Active Aurora A (pAurora A) expression is amplified when treated with 
Nocodazole. Alisertib treatment caused the inhibition of active Aurora A. The 
loading control was normalized to the untreated condition for both Alisertib and 
Nocodazole. Aurora A was quantified by initially normalizing it with the 
respective loading control and comparing it with the untreated condition.   
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undetectable levels, in both the presence and absence of nocodazole treatment. The levels of 
total Aurora A were equal among the conditions. Tubulin was used as a loading control to 
ensure that the increase in pAurA was not due to the loading of more protein. 
 
To determine the effects of Alisertib treatment at different concentrations in control and AML cell 
lines, viability assays were performed (Figure 16). This assay determines the number of viable 
cells after being treated with Alisertib for 72 hours, which were normalized with their respective 
untreated condition. Five AML cell lines (KG1α, HL60, K562, U937, and THP1) and three 
controls (RPE-1, PC9, and SAOS2) were exposed to increasing concentrations of Alisertib. The 
 
Viability assays were used to assess cell viability in each cell line with concentrations of Alisertib. K562 
and U937 both scored to have reduced drug sensitivity to Alisertib. Standard Deviation is  1 way 
ANOVA: P value < 0.05 (*), P value < 0.01 (**), P value < 0.001 (***).  
Figure 16. AML and Control Cell Lines Viability at Concentrations of Alisertib 
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three controls experienced a significant decrease (p = ) in viability when treating with 250nM 
concentrations of the drug. In contrast, AML viability to Alisertib concentration was dependent 
on the cell line. HL60 and KG1α appeared to be the most sensitive AML cell lines, since they 
experienced a significant decrease in cell viability when treated with 10nM and 25nM of Alisertib, 
respectively. Alternatively, K562 and U937 were the most resistant cell lines, and experienced a 
significant decrease when treated with a 250nM concentration. Because of that, additional 
viability assays were 
performed with higher 
Alisertib concentrations 
(500nM, 750nM, and 1uM) 
using these two AML-
resistant cell lines and the 
control RPE-1. RPE-1 and 
U937 behaved similarly, 
with only 10% of viable 
cells at a 1uM 
concentration. However, 
the increase in the 
treatment concentration did 
not have an effect in K562, 
which maintained a similar 
percentage of viable cells.   
 
To further examine the 
effect of Alisertib treatment 
on AML cells, 
immunofluorescence 
imaging was performed. 
Cells were left untreated, 
or treated with 25nM, 50nM, 
or 100nM of Alisertib for 
14h. The percent of cells 
arrested in mitosis and the 
spindle polarity of the mitotic cells were examined for all conditions. AML cell lines experienced 
Figure 18 FACS analysis Cell Cycle of AML cells treated with Alisertib 
FACS analysis showed an increase in the number of cells in mitosis, specially 
in the cell lines U937 and K562, after treatment with Alisertib at 100nM and 
250nM concentrations. This arrest is dose-dependent.  
Figure 17. Mitotic Index for AML Cells Treated with Alisertib 
Immunofluoresence was used to score mitotic index for AML cells 
treated with varying concentrations of Alisertib. K562, KG1α  and HL60 
experienced significant increases in mitotic index at 50 and 100 nM of 
Alisertib. Standard Deviation is  1 way ANOVA: P value < 0.05 (*), P 
value < 0.01 (**), P value < 0.001 (***).   
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an increase in mitotic arrest with increasing concentrations of Alisertib (Figure 17), K562 being 
the cell line that expressed a higher number of cells in mitosis compared with other AML cell 
lines. On the contrary, the control 
cell line RPE did not experience 
an increase in mitotic cells. FACS 
analysis was performed to confirm 
the increase in mitosis, which 
positively correlated with the 
concentration of Alisertib used 
(Figure 18). 
 
Spindle polarity of mitotic cells was 
also examined (Figure 19 and 
Figure 20), exhibiting a dose-
dependent increase in 
monopolarity. RPE-1 cells, used 
as controls, expressed a 46% of 
monopolar spindles when treated 
with 50nM of Alisertib, which was 
further increased to 67% when the 
treatment concentration was 
increased to 100nM. Regarding 
AML cell lines, most of them 
already expressed a higher 
number of monopolar spindles 
before treatment, which was 
increased significantly up to 95%. 
In the case of K562, the opposite 
results were observed. As the 
concentration of Alisertib 
increased, fewer cells were 
expressing monopolar spindles in 
favor of multipolar and 
disorganized spindle expression.   
Figure 19. Immunofluorescence Analysis on Spindle Polarity 
after Alisertib Treatment 
Treatment of AML cell lines with Alisertib (100nM and 250nM) caused 
the formation of monopolar spindle poles in control and representative 
cell line KG1α. However, resistant cell line K562 did not increase the 
number of monopolar spindle poles. 
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One explanation as to why cells 
might be resistant to alisertib 
would be if they failed to maintain 
a mitotic arrest and were instead 
able to proceed to anaphase.  To 
determine if this could explain 
reduced sensitivity in the K562 cell 
line, we next determined the 
percentage of mitotic cells that are 
in anaphase when treating with 
Alisertib. Sensitive cell line HL60, 
was examined for comparison. 
When treated with two 
concentrations of Alisertib (50nM 
and 100nM), the resistant AML cell line K562 exhibited x % of cells in anaphase, a significantly 
higher number than compared with the sensitive AML cell line HL60. Although increasing 
concentrations of Alisertib limited anaphase cells in both cell lines, K562 maintained a higher 
percentage of anaphase cells then 
HL60 at both low and high doses 
of Alisertib (Figure 21)   
 
4.4 Centriole amplification 
independently from Aurora A 
overexpression causes resistance 
to Alisertib treatment  
 
Because previous experiments 
depicted a correlation between 
Aurora A overexpression, 
centrosome amplification and 
resistance to Alisertib treatment, 
we designed new experiments in 
which we could amplify centrosomes in an Aurora A independent manner to determine whether 
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Figure 21. Percent of Mitotic cells in Anaphase 
Alisertib-resistant AML cell line K562 exhibited a significantly increased 
number of mitotic cells in anaphase compared with Alisertib-sensitive 
AML cell line.   
Figure 20 Percentage of mitotic cells expressing monopolarity 
Treatment with Alisertib causes control and most AML cell lines to 
express monopolar spindles when they are in mitosis. On the other 
hand, Alisertib-resistant AML cell line K562, reduced the number of 
mitotic cells expressing a monopolar spindle.  
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Aurora A overexpression or centrosome amplification is causing the AML cell lines to be less 
sensitive to treatment. This was done using a RPE-1 cell line that expresses polo like kinase 4 
under a tetracycline-on promoter.  Polo-like kinase 4 (PLK-4) is a cell cycle kinase involved in 
centrosome maturation. When overexpressed, PLK-4 can induce centriole amplification by 
producing multiple procentrioles that adjoin to the parental centriole (Kleylein-Sohn et al, 2007). 
In a Tet-on regulated system, the expression of the gene under the promoter is controlled by the 
presence of tetracycline or doxycycline (Zhou, et. al., 2006). The addition of doxycycline in our 
experiments inhibits the interaction of the tet-repressor protein with the tet-operator because of 
a conformational change (Zhou, et. al., 2006). Additionally, the tet-repressor protein binds to the 
domain of the V16 protein, which is derived from herpes simple virus. In a tet-on system, the tet-
repressor protein contains a change in amino acids that causes it to express the opposite 
phenotype (Zhou, et. al., 2006). This means that in the presence of doxycycline, the reverse tet-
activator (rtTA) binds to the tet-operator (tetO) and it causes the expression of the gene (Zhou, 
et. al., 2006).  Doxycycline was used in order to cause the overexpression of Plk-4. To confirm 
the effects on centriole number as well as spindle polarity, immunofluorescence analysis was 
used (Figure 23).  
 
Figure 22A shows the PLK-4 plasmid, and its transcription is activated by the addition of doxycycline. 
Figure 22B shows the experimental set-up of the induction of PLK-4 overexpression in RPE-1 cells. 
Doxycycline is added to RPE-PLK-4 cells, which results in the overexpression of  PLK-4. This leads to 
the formation of additional procentrioles leading to the development of mature centrioles.  
A 
B 
Figure 22. PLK-4 Overexpression Experimental Layout 
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The cells that were cultured without the addition of doxycycline express a single centrosome 
during interphase, which gets duplicated during mitosis. The addition of doxycycline for 48h 
caused the amplification of centrioles, in both interphase cells as well as during mitosis. This 
caused the spindle polarity to also be affected, with 60% of mitotic cells overexpressing PLK-4 
having a multipolar spindle formation. This data confirms that the induction of PLK-4 in the 
RPE1 PLK-4 cell line can successfully induce the amplification of centrioles. 
 
Immunoflourescence analysis of  PLK-4 RPE-1 cells to confirm overexpression of PLK-4 and 
centriole amplification as a result.  
Figure 23. PLK-4 Overexpression and Centriole Amplification Confirmation 
 
 
P a g e  | 31 
 
To understand how 
centriole amplification 
affects cells treated with 
Alisertib, 
immunofluorescence 
analysis as well as 
viability assays were 
performed. First, mitotic 
index for cells in all 
conditions was 
determined. There were 
no significant differences 
in the number of cells in 
mitosis between RPE-1 
cells that had normal and 
Plk-4 overexpression, 
with about 2% of the cells 
being in mitosis. Moreover, treatment with Alisertib causes a slight, but insignificant increase in 
mitosis in a dose-dependent manner (Figure 24).  
 
Next, we examined the effect of centriole amplification on monopolar spindle formation using 
Alisertib to inhibit Aurora A kinase in the RPE-1 cells, with or without induction of PLK-4 
overexpression (Figure 25). Overexpression of Plk-4 in untreated cells caused an increase in 
the number of cells expressing multipolar spindles, and a concurrent decrease in cells exhibiting 
a bipolar spindle. Treatment with Alisertib in the cells that are overexpressing Plk-4 did not 
cause an increase in monopolarity. On the other hand, there can be seen an increase in the 
number of cells that express a disorganized spindle pole, as the concentration of Alisertib 
increases.  
 
In a couple of the analyzed AML cell lines (K562 and U937) centriole amplification and reduced 
sensitivity to Alisertib were observed. To examine the role of centriole number in Alisertib 
sensitivity, without additional factors such as Aurora A overexpression the RPE-1 PLK-4 
overexpressed cell line was used. The cell with regular levels of PLK-4 expression behaved 
comparably to the RPE-1 cells in Figure 12, showing a significant decrease in cell viability at 50 
Mitotic index was scored in normal and overexpressed PLK-4 cells in 50 and 100 
nM of Alisertib. Both normal and overexpressed PLK-4 cells showed an increased 
mitotic index as Alisertib concentrations increased.  
Figure 24. Mitotic Index of Normal and Overexpressed PLK-4 Cells 
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nM. In the cells with 
PLK-4 overexpression, 
there was not a 
significant decrease in 
cell survival until 250 nM 
(Figure 26). This is 
similar to what was 
observed in the K562 
and U937 cell lines in 
(Figure 16). These 
results demonstrate that 
increases centriole 
number is a contributing 
factor in resistance to 
induced monopolarity 
and may impact 
decreased sensitivity of 
AML cancer cells to 
Alisertib treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Spindle Polarity of RPE cells with and without overexpression of 
Plk-4  
Overexpression of Plk-4 in RPE cells causes them to express a high percentage of 
multipolar spindle poles, as well as a disorganized phenotype when the 
concentration of Alisertib increases  
 
 
Viability assays were used to assess the cell viability of normal and overexpressed 
PLK-4 cells at concentrations of Alisertib. Overexpressed PLK-4 cells did not show 
a significant decrease in cell survival until 250 nM. Standard Deviation is 1 way 
ANOVA: P value < 0.05 (*), P value < 0.01 (**), P value < 0.001 (***) 
Figure 26. Normal and Overexpressed PLK-4 Cell Viability Alisertib Treatment 
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5. Discussion  
 
Aurora A has been characterized to have several roles during mitosis, such as mitotic spindle 
assembly, centrosome separation, and G2-M transition, among others. The disregulation of this 
kinase has serious effects on the cell, as it causes many defects on mitotic spindle formation, 
chromosome separation, and increases genomic instability. Aurora A kinase has risen as a 
possible target for the development of new therapeutics, since it has been shown to be 
overexpressed in a number of different cancers, such as liver cancer. In this context, research 
has also revealed that many patients suffering from acute myeloid leukemia also exhibit an 
overexpression of this kinase. Alisertib, a specific inhibitor of AurA function, is being used in 
clinical trials in order to determine its effectiveness on AML patients. Our results indicate that 
AML cell lines respond to Alisertib treatment differently, and suggest the number of centrioles 
could be affecting the effectiveness of treatment.  
 
Characterization of the AML cell lines started by determining which of those showed an 
overexpression of Aurora A, and K562 and U937 were the two cell lines to show the highest 
amount of Aurora A expression during unsychronized and synchronized states (Figure 11). 
These two cell lines that overexpress Aurora A, also amplified the number of centrioles (Figure 
14) when immunofluorescence analysis was performed. This could be a direct result of Aurora A 
overexpression, since Aurora A plays an indirect role in centriole duplication. Lastly, spindle 
polarity was also determined for control and AML cell lines. K562, one of the cell lines that 
showed amplified number of centrioles, exhibited a number of cells in multipolar and 
disorganized spindle poles. On the other hand, other AML cell line which express a normal 
number of centrioles and do not overexpress Aurora A at the high levels of K562 and U937, 
exhibited a higher amount of monopolar spindles compared with the control RPE-1 (Figure 13).  
 
The effect that Alisertib has on AML was next addressed, after concluding that Alisertib is able 
to inhibit active Aurora A (phosphorylated Aurora A) in K562, even when the cells are treated 
with Nocodazole to cause their arrest in mitosis, the stage in mitosis in which Aurora A is active 
(Figure 15). Cells that overexpress Aurora A and amplify centriole number showed the need for 
a higher concentration of Alisertib for cells not to be viable. K562, showed the most resistance 
to Alisertib treatment, while other AML cell lines exhibited a significant decrease in cell viability 
with lower concentrations of the drug (Figure 16). Treatment with Alisertib caused the arrest of 
AML cell lines in mitosis, in a dose-dependent manner (Figure 17 and Figure 18). When 
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determining the spindle polarity of the cells arrested after Alisertib treatment we also see a 
correlation between those cell lines that overexpress Aurora A more and amplify centrioles and 
those which do not. While the AML cell lines that express a normal number of centrioles and 
Aurora A exhibit a monopolar spindle pole, those that overexpress Aurora A and exhibit 
increased centrioles number decrease the amount of monopolar cells, and show an increase in 
multipolar and disorganized spindle poles (Figure 19). Moreover, the number of mitotic cells in 
anaphase after treatment with Alisertib is significantly greater than an Alisertib-sensitive cell line, 
such as HL60 (Figure 20).  
 
Alisertib is the most specific Aurora A inhibitor up to date. However, as many of the other Aurora 
A inhibitors, this drug can also be specific for other Aurora kinases, such as Aurora B kinase, at 
higher concentrations. Based on this, the decrease in cell viability that we observe on some 
AML cell lines is likely due to inhibition of Aurora A, since a low concentration of Alisertib, such 
as 25nM, already causes a significant decrease (Figure 16). It is possible that the cell lines that 
are more resistant and do not show a decrease in viability after an increase in Alisertib 
concentration are due to Alisertib inhibiting other targets such as Aurora B. There is a need then 
for performing similar experiments with other Aurora A inhibitors to confirm the results.  
 
Because of these results, and in order to separate the expression of Aurora A to the one of 
centrioles, we used RPE engineered cells to overexpress Plk-4, which allowed us to induce 
centriole amplification (Figure 22). This overexpression of centrioles affected the cellular 
changes when they were treated with different concentrations of Alisertib. Those that expressed 
amplified centrioles maintained a multipolar spindle phenotype when treated with Alisertib 
(Figure 25). In addition, cells with PLK-4 overexpression had a reduced Alisertib sensitivity 
compared to the cells with normal levels of PLK-4 (Figure 26).  The cells without PLK-4 
overexpression experienced a decrease in cell survival at 50 nM Alisertib, whereas the cells 
viability was not significantly affected in cells overexpressing PLK-4 until 250 nM. At Alisertib 
concentrations higher than 250 nM, both cell types were sensitive to the drug and cell survival 
decreased significantly. From these experiments, we conclude that centriole abundance may 
play a role in reduced drug sensitivity. Because of these results, two more experiments were 
designed. In order to ensure that results that we obtained are due to an amplification of 
centrioles and not the overexpression of Plk-4 itself, HCT116 cells expressing a p53 knockout 
were used and treated with the drug cytochalasin B. This drug acts by shortening filaments and 
prevents the completion of cytokinesis, which leads to the acquisition of multiple centrioles after 
 
 
P a g e  | 35 
 
a cell cycle failure. The cells need to have a defective p53 status, which allows the cells to 
continue through the cell cycle even with an amplification of centrosomes.  
 
Additionally, live cell imaging is being performed on RPE with or without overexpression of 
centrioles to understand the effects it has on cell fate when treated with different concentrations 
of Alisertib. This allows the visualization of the cells during a 16h period of time and the 
determination of whether cells arrest in mitosis, continue the cell cycle, or exit mitosis.  
 
While centriole number may play a role in Alisertib sensitivity and monopolar spindle formation, 
the mechanism of this action and other cellular factors that may contribute were not investigated. 
Therefore, work on this project could address the effects of overexpression of Aurora A in RPE 
or non AML cell lines and determine the cell’s sensitivity to Alisertib. This would help to decipher 
if Aurora A overexpression has a significant impact on the monopolar spindle pole formation or 
the sensitivity of the cells to Alisertib. Loss of PLK-4 has been shown to prevent centriole 
duplication (Holland et al., 2012) Therefore, to further test the impact of centrosome number on 
Alisertib sensitivity, it would also be interesting to reduce the expression of PLK-4 in K562 (the 
cell line with an increase in centriole number), to observe the impact of reduced centriole 
number in these cell lines. This would provide additional insight into the relationship of centriole 
abundance and drug sensitivity.  
 
To further understand the relevance of centriole abundance and drug sensitivity, in vivo models 
could be utilized to further assess what factors impact the effectiveness of Alisertib. This 
experiment would be used to support previous experiments and also explore the potential 
effects of centriole amplifications in tumor growth and treatment in living models.  
 
These results could lead to further patient studies, where blood samples from each patient are 
taken and their cellular structure is analyzed. If their cells show signs of centriole abundance, 
physicians may instruct the patients to use higher dosing or even a treatment different from 
Alisertib or use a combination of therapies to target the leukemic cells in addition to Alisertib. 
This would be an initial step to creating patient profile that would indicate drug efficacy based on 
cellular phenotype.  
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